Zev A. Wainberg, MD

Zev A. Wainberg, MD, discusses the rapidly evolving landscape of KRAS-directed therapy in PDAC from pan-RAS inhibition to KRAS G12D–specific strategies.

Frontline HER2-positive gastric cancer trials test T-DXd combos and TIGIT/PD-L1 bispecifics, aiming to improve survival beyond trastuzumab.

Experts weigh T‑DXd as second-line HER2+ gastric cancer therapy, stressing rebiopsy/ctDNA and vigilant pneumonitis risk.

Experts weigh T‑DXd for HER2+ gastric cancer after prior therapy, stressing rebiopsy or ctDNA confirmation and vigilant pneumonitis monitoring.

Clinicians share real-world tips to prevent and manage zanidatamab-related diarrhea, using early loperamide, patient counseling, follow-up calls, and supportive care.

Experts weigh using triplet immunotherapy plus chemo for PD‑L1–negative patients, balancing survival gains, side effects, and FDA approval in first-line care.

New trial updates tease stronger survival with zanidatumab combos; two analyses ahead may clarify OS, biomarkers, and tislelizumab’s added value.

New HER2+ gastric cancer data show triplet immunotherapy boosts survival and durable responses, hinting immune activation beyond HER2 targets.

HORIZON GEA 01 shows zanidatamab regimens significantly improve survival in HER2-positive gastric, esophageal, and GEJ cancer, while PD-L1 testing differences raise key questions for treatment choice.

Experts debate PD‑L1 testing in HER2+ metastatic gastric cancer as new trial data reshapes when to add immunotherapy.

Zanidatamab’s dual HER2 binding shows striking single-agent activity in gastric and biliary cancers, hinting at synergy beyond pertuzumab-trastuzumab blockade.

Experts unpack zanidatamab’s dual HER2 binding, why JACOB nearly succeeds, and what standout gastric and biliary cancer responses mean next.

Clinicians explain zanidatamab’s action and HORIZON-GEA-01

Zev A. Wainberg, MD, discusses current available frontline chemotherapy regimens for patients with metastatic pancreatic cancer.

Zev A. Wainberg, MD, MSc, outlines factors informing his choice between standard frontline chemotherapy regimens in metastatic pancreatic cancer.

Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, discuss ongoing trials that could help refine the gastric/GEJ cancer treatment paradigm.

Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, discuss other key gastric cancer data presented at the 2025 ESMO Congress.

Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, discuss the potential clinical implications of the investigation of domvanalimab plus zimberelimab and FOLFOX in gastric/GEJ/esophageal adenocarcinoma.

Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, detail the design of the phase 3 STAR-221 trial comparing domvanalimab plus zimberelimab and FOLFOX with nivolumab plus chemotherapy for first-line advanced gastric, GEJ, or esophageal adenocarcinoma. They discuss why nivolumab plus chemotherapy serves as an appropriate control arm and the importance of head-to-head evidence in clarifying comparative benefit across immunotherapy combinations. They review the study’s primary endpoints and overall goals, including survival outcomes and the potential to redefine the frontline standard.

Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, discuss the implications of findings from the phase 2 EDGE-Gastric trial.

Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, discuss current treatment standards in advanced gastric/GEJ cancer.

Leading experts across oncology specialties preview the key studies and data they are most anticipating ahead of the 2025 ESMO Congress.

Zev A. Wainberg, MD, MSc, highlighted notable research in gastric cancer and cholangiocarcinoma presented during the 2025 ESMO GI Congress.

Zev A. Wainberg, MD, MSc, discusses data from the EDGE-Gastric trial of domvanalimab plus zimberelimab and FOLFOX in first-line, metastatic gastric cancer.

Zev A. Wainberg, MD, discusses findings from the phase 2/3 ASPEN-06 trial (NCT05002127) of evorpacept plus trastuzumab, ramucirumab, and paclitaxel in HER2-overexpressing gastric/GEJ cancer.

Dr Wainberg discusses the FDA approval of first-line NALIRIFOX for patients with metastatic pancreatic adenocarcinoma.

Zev A. Wainberg, MD, discusses the FDA approval of NALIRIFOX for patients with metastatic pancreatic ductal adenocarcinoma.

Zev A. Wainberg, MD, discusses the rationale behind the phase 3 NAPOLI 3 trial in patients with metastatic pancreatic ductal adenocarcinoma.

Zev A. Wainberg, MD, discusses the evaluation of liposomal irinotecan plus 5-fluorouracil leucovorin, and oxaliplatin vs nab-paclitaxel plus gemcitabine in the phase 3 NAPOLI 3 trial in patients with metastatic pancreatic ductal adenocarcinoma.

Zev A. Wainberg, MD, discusses standard frontline treatment approaches for patients with metastatic esophageal squamous cell carcinoma and highlights data supporting the use of tislelizumab in combination with chemotherapy in ESCC.